These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

651 related articles for article (PubMed ID: 12471615)

  • 61. Long-term Behavior of Serous Borderline Tumors Subdivided Into Atypical Proliferative Tumors and Noninvasive Low-grade Carcinomas: A Population-based Clinicopathologic Study of 942 Cases.
    Vang R; Hannibal CG; Junge J; Frederiksen K; Kjaer SK; Kurman RJ
    Am J Surg Pathol; 2017 Jun; 41(6):725-737. PubMed ID: 28248817
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Fascin expression in serous tumors of ovary correlates with aggressiveness of malignancy.
    Wen YH; Yee H; Goswami S; Shukla PS
    Int J Gynecol Pathol; 2009 Mar; 28(2):187-92. PubMed ID: 19188814
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators.
    Seidman JD; Kurman RJ
    Hum Pathol; 2000 May; 31(5):539-57. PubMed ID: 10836293
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Lymphatic metastasis and VEGF-C expression in ovarian epithelial tumors].
    Ding MX; Li JC; Tang XH
    Shi Yan Sheng Wu Xue Bao; 2003 Dec; 36(6):445-52. PubMed ID: 14724935
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Analysis of telomerase activity in ovarian cystadenomas, low-malignant-potential tumors, and invasive carcinomas.
    Datar RH; Naritoku WY; Li P; Tsao-Wei D; Groshen S; Taylor CR; Imam SA
    Gynecol Oncol; 1999 Sep; 74(3):338-45. PubMed ID: 10479490
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Follicle-stimulating hormone receptor is expressed in human ovarian surface epithelium and fallopian tube.
    Zheng W; Magid MS; Kramer EE; Chen YT
    Am J Pathol; 1996 Jan; 148(1):47-53. PubMed ID: 8546225
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Androgen receptor and follicle-stimulating hormone receptor in the pig ovary during the follicular phase of the estrous cycle.
    Cárdenas H; Pope WF
    Mol Reprod Dev; 2002 May; 62(1):92-8. PubMed ID: 11933165
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Localization and expression of follicle-stimulating hormone receptor gene in buffalo (Bubalus bubalis) pre-antral follicles.
    Sharma GT; Dubey PK; Kumar GS
    Reprod Domest Anim; 2011 Feb; 46(1):114-20. PubMed ID: 20403128
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Flow cytometry and AgNORs in benign, borderline, and malignant mucinous and serous tumours of the ovary.
    Griffiths AP; Cross D; Kingston RE; Harkin P; Wells M; Quirke P
    Int J Gynecol Pathol; 1993 Oct; 12(4):307-14. PubMed ID: 8253547
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Expression of the retinoblastoma-related gene Rb2/p130 in the pathogenesis of serous carcinoma of the ovary.
    Worley MJ; Landen CN; Slomovitz BM; Malpica A; Palla SL; Ramirez PT
    Appl Immunohistochem Mol Morphol; 2010 Dec; 18(6):509-11. PubMed ID: 20661130
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Downregulation of follicle-stimulating hormone (FSH)-receptor messenger RNA levels in the hamster ovary: effect of the endogenous and exogenous FSH.
    Zhang YM; Roy SK
    Biol Reprod; 2004 Jun; 70(6):1580-8. PubMed ID: 14749302
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cell-nonautonomous induction of ovarian and uterine serous cystadenomas in mice lacking a functional Brca1 in ovarian granulosa cells.
    Chodankar R; Kwang S; Sangiorgi F; Hong H; Yen HY; Deng C; Pike MC; Shuler CF; Maxson R; Dubeau L
    Curr Biol; 2005 Mar; 15(6):561-5. PubMed ID: 15797026
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Follicle stimulating hormone receptor in ovarian surface epithelium and epithelial ovarian cancer.
    Bose CK
    Oncol Res; 2008; 17(5):231-8. PubMed ID: 18980020
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Expression of hSef and FGF-2 in epithelial ovarian tumor].
    Feng QL; Shi HR; Qiao LJ; Zhao J
    Zhonghua Zhong Liu Za Zhi; 2011 Oct; 33(10):770-4. PubMed ID: 22335910
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Molecular genetic analysis of ovarian serous cystadenomas.
    Cheng EJ; Kurman RJ; Wang M; Oldt R; Wang BG; Berman DM; Shih IeM
    Lab Invest; 2004 Jun; 84(6):778-84. PubMed ID: 15077125
    [TBL] [Abstract][Full Text] [Related]  

  • 76. MORPHOPHENOTYPIC CHARACTERISTICS OF OVARIAN SEROUS BORDERLINE TUMORS.
    Munjishvili V; Barabadze E; Musashvili T; Gachechiladze M; Burkadze G
    Georgian Med News; 2019 May; (290):20-25. PubMed ID: 31322508
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Clinical and prognostic significance of lost or decreased PDCD5 expression in human epithelial ovarian carcinomas.
    Zhang X; Wang X; Song X; Wei Z; Zhou C; Zhu F; Wang Q; Ma C; Zhang L
    Oncol Rep; 2011 Feb; 25(2):353-8. PubMed ID: 21165576
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Expression and mutational analysis of c-kit in ovarian surface epithelial tumors.
    Kim DJ; Lee MH; Park TI; Bae HI
    J Korean Med Sci; 2006 Feb; 21(1):81-5. PubMed ID: 16479070
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Molecular genetic evidence of an independent origin of serous low malignant potential implants and lymph node inclusions.
    Emerson RE; Wang M; Liu F; Lawrence WD; Abdul-Karim FW; Cheng L
    Int J Gynecol Pathol; 2007 Oct; 26(4):387-94. PubMed ID: 17885488
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Ovarian mixed-epithelial papillary cystadenomas of borderline malignancy of mullerian type. A clinicopathologic analysis.
    Rutgers JL; Scully RE
    Cancer; 1988 Feb; 61(3):546-54. PubMed ID: 3338022
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.